Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia

NCT01681537 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01681537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01681537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2015
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia